Literature DB >> 14998778

Effectiveness of live varicella vaccine.

Michiaki Takahashi1.   

Abstract

The disease burden of chickenpox to children has been described, and a lower force of neutralising antibody to varicella-zoster virus (VZV) than against measles, either after natural infection or after vaccination, has been reported. In the case of VZV, strong cell-mediated immunity may work efficiently to prevent the spread of the virus. The lower force of humoral antibody to VZV might be related to the occurrence of "breakthrough" varicella cases in a small portion of the vaccine recipients. Safety and high effectiveness of the varicella vaccine--approximately 85% effective for all diseases and 95-100% effective for moderate-to-severe diseases--have been reported. Vaccine-induced immunity persists for 10-20 years. However, concerns have been raised that universal immunisation in children may shift the susceptibility from children to adults, whose symptoms are usually moderate-to-severe. In addition, other concerns have been expressed that, due to lack of exposure to varicella in children, the elderly may develop zoster infections more frequently than before. A clear answer is difficult to give at present, although, for several reasons, such situations may be unlikely to occur.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14998778     DOI: 10.1517/14712598.4.2.199

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  14 in total

1.  Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.

Authors:  Catia T Perciani; Bashir Farah; Rupert Kaul; Mario A Ostrowski; Salaheddin M Mahmud; Omu Anzala; Walter Jaoko; Kelly S MacDonald
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 14.808

2.  Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.

Authors:  Masahiro Onozawa; Satoshi Hashino; Mutsumi Takahata; Fumie Fujisawa; Takahito Kawamura; Masao Nakagawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

3.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

4.  Clinical and molecular aspects of varicella zoster virus infection.

Authors:  Don Gilden; Maria A Nagel; Ravi Mahalingam; Niklaus H Mueller; Elizabeth A Brazeau; Subbiah Pugazhenthi; Randall J Cohrs
Journal:  Future Neurol       Date:  2009-01-01

Review 5.  Neurovirulence of varicella and the live attenuated varicella vaccine virus.

Authors:  Corey Horien; Charles Grose
Journal:  Semin Pediatr Neurol       Date:  2012-09       Impact factor: 1.636

6.  The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.

Authors:  Geoffrey A Peters; Shaun D Tyler; John E Carpenter; Wallen Jackson; Yasuko Mori; Ann M Arvin; Charles Grose
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

7.  Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus.

Authors:  Randall J Cohrs; Donald H Gilden; Yasuyuki Gomi; Koichi Yamanishi; Jeffrey I Cohen
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 8.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

9.  Bioinformatics of varicella-zoster virus: single nucleotide polymorphisms define clades and attenuated vaccine genotypes.

Authors:  Vincent T Chow; Graham A Tipples; Charles Grose
Journal:  Infect Genet Evol       Date:  2012-11-24       Impact factor: 3.342

10.  Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children.

Authors:  Amaran Moodley; Jack Swanson; Charles Grose; Daniel J Bonthius
Journal:  J Child Neurol       Date:  2019-01-10       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.